Related Experiment Videos
Platelet inhibition in percutaneous coronary interventions
Christophe A Wyss1, Marco Roffi
1Department of Cardiology, University Hospital Zurich, Switzerland.
Herz
|May 20, 2005
Summary
Aspirin and thienopyridines like clopidogrel are vital for preventing blood clots during percutaneous coronary intervention (PCI). High-risk patients may benefit from glycoprotein IIb/IIIa antagonists.
Area of Science:
- Cardiology
- Hematology
- Interventional Cardiology
Background:
- Percutaneous coronary intervention (PCI) can trigger arterial thrombosis due to plaque disruption.
- Platelets are central to clot formation, necessitating effective platelet inhibition during PCI.
Purpose of the Study:
- To outline the essential role of antiplatelet therapy in managing patients undergoing PCI.
- To define the optimal antithrombotic strategy for successful PCI and prevention of device thrombosis.
Main Methods:
- Review of current antithrombotic guidelines and evidence for PCI.
- Focus on the use of aspirin, thienopyridines (e.g., clopidogrel), and glycoprotein IIb/IIIa antagonists.
Main Results:
- Aspirin is fundamental to antithrombotic therapy in PCI.
- Thienopyridines are mandatory post-stenting to prevent device thrombosis, with clopidogrel recommended for up to one year.
- Glycoprotein IIb/IIIa antagonists are indicated for high-risk PCI patients.
Conclusions:
- A comprehensive antiplatelet strategy is crucial for successful PCI.
- Tailoring antithrombotic therapy based on patient risk factors and procedure complexity optimizes outcomes.